Dyve Biosciences is a pioneering biotech company based in Camarillo, CA, that specializes in leveraging their groundbreaking DMAX transdermal platform to deliver targeted pH modulation for the treatment of various immunologic and oncologic diseases. By directly targeting the acidic microenvironments that drive cancer cell growth and inflammation, Dyve Biosciences aims to translate proven scientific advancements from the lab to patient care, offering a potentially transformative approach to disease treatment.
With their lead products DYV800 and DYV700, Dyve Biosciences focuses on neutralizing acidic microenvironments to treat a range of immunologic and oncologic diseases. Their patented approach to pH modulation seeks to reverse the extracellular conditions that contribute to disease progression, leading to improved outcomes. By utilizing their DMAX platform, which enables the delivery of pH-modulating agents and other molecules that are unsuitable for oral or injectable administration, Dyve Biosciences aims to expand the treatment horizon and set a new standard of care in the fields of oncology and immunology.
Generated from the website